Stock page
Cullgen Inc (CUGN)
Cullgen Inc is clinical-stage biopharmaceutical company. The company is engaged in the development of medicines for the treatment of diseases lacking effective therapeutic approaches. The company utilizes its technology platform, uSMIT, featuring novel E3 ligands, to build the next generation of targeted protein degraders and to discover and advance therapeutics for the treatment of cancer and other diseases. The products in the company's pipeline include Degrader TRK, Degrader GSPT1, DAC, and others.
Quote snapshot
$0.00
Daily change: —
ExchangeNAS
Updated2026-05-09T04:30:56.280581Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|